Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase Ib Trial Evaluating the Safety of Copanlisib, Letrozole, and Palbociclib in Metastatic Breast Cancer and Phase II Trial Comparing the Molecular Effects of Neoadjuvant Copanlisib in Combination With Palbociclib and Letrozole, vs. Copanlisib With Letrozole, vs. Palbociclib With Letrozole for Patients With Hormone Receptor Positive, HER2 Normal Breast Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03128619
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:38:58.810719+00:00
Published At
2022-09-26T00:00:00+00:00
Record Updated At
2022-09-26
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Estrogen Receptor Positive", "HER2/Neu Negative", "Invasive Breast Carcinoma", "Multifocal Breast Carcinoma", "Postmenopausal", "Progesterone Receptor Positive", "Stage I Breast Cancer", "Stage IA Breast Cancer", "Stage IB Breast Cancer", "Stage II Breast Cancer", "Stage IIA Breast Cancer", "Stage IIB Breast Cancer", "Stage III Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2022-09-26"
protocolSection.identificationModule.nctId
"NCT03128619"
protocolSection.identificationModule.officialTitle
"A Phase Ib Trial Evaluating the Safety of Copanlisib, Letrozole, and Palbociclib in Metastatic Breast Cancer and Phase II Trial Comparing the Molecular Effects of Neoadjuvant Copanlisib in Combination With Palbociclib and Letrozole, vs. Copanlisib With Letrozole, vs. Palbociclib With Letrozole for Patients With Hormone Receptor Positive, HER2 Normal Breast Cancer"
protocolSection.statusModule.overallStatus
"TERMINATED"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Estrogen Receptor Positive (protocolSection.conditionsModule.conditions)
  • HER2/Neu Negative (protocolSection.conditionsModule.conditions)
  • Invasive Breast Carcinoma (protocolSection.conditionsModule.conditions)
  • Multifocal Breast Carcinoma (protocolSection.conditionsModule.conditions)
  • Postmenopausal (protocolSection.conditionsModule.conditions)
  • Progesterone Receptor Positive (protocolSection.conditionsModule.conditions)
  • Stage I Breast Cancer (protocolSection.conditionsModule.conditions)
  • Stage IA Breast Cancer (protocolSection.conditionsModule.conditions)
  • Stage IB Breast Cancer (protocolSection.conditionsModule.conditions)
  • Stage II Breast Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIA Breast Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIB Breast Cancer (protocolSection.conditionsModule.conditions)
  • Stage III Breast Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIA Breast Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIB Breast Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIC Breast Cancer (protocolSection.conditionsModule.conditions)
  • Stage IV Breast Cancer (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.